IFW

ATTORNEY DOCKET NO. 21108.0034U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	
	)	
Smith *et al.*	)	Art Unit: Unassigned
	)	
Application No. 10/523,038	)	Examiner: Unassigned
	)	
Intl. Filing Date: August 5, 2003	)	Confirmation No. 6473
	)	
For: PROTEIN TRANSDUCING DOMAIN/ DEAMINASE CHIMERIC PROTEINS, RELATED COMPOUNDS AND USES THEREOF	)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.

Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Tina W. McKeon
Registration No. 43,791

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Tina W. McKeon — November 29, 2005 (Date)

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/523,038
Intl. Filing Date	8/5/2003
First Named Inventor	Smith, H., *et al.*
Group Art Unit	1648
Examiner Name	Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate
	A1	6,653,443	11/25/03	Zhang			
	A2	6,653,443	11/25/03	Hui et al.			
	A3	6,331,311	12/18/01	Brodbeck et al.			
	A4	6,087,108	07/11/00	Bandman et al.			
	A5	6,041,253	03/21/00	Kost et al.			
	A6	5,916,556	06/29/99	Au-Young et al.			
	A7	5,866,333	02/02/99	Innerarity et al.			
	A8	5,804,185	09/08/98	Bandman			
	A9	5,747,319	05/05/98	Au-Young			
	A10	5,468,022	11/21/95	Linder et al.			
	A11	20020164743	11/07/02	Honjo et al.			
	A12	20040115184	06/17/04	Smith et al.			
	A13	20050112555	05/26/05	Smith et al.			

FOREIGN PATENT DOCUMENTS

	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A14	WO 02/068676	09/06/02	University of Rochester	
	A15	EP 0 789 206	08/13/97	Bosch Siemens Hausgeraeta	
	A16	EP 0 568 510	11/03/93	Partex Fabriks AB	
	A17	EP 1 174 509	01/23/02	Kansai Technology Licensing Organization Co., Ltd.	
	A18	CH 502 546	01/31/71	Guido et al.	

NON-PATENT CITATION DOCUMENTS

	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A19	Abad et al., Single-step, multiple retroviral transduction of human T cells. *J Gene Med* 4: 27-37 (2002).
	A20	Ahl et al., Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization. *Biochim Biophys Acta.* 1329:370-382 (1997)
	A21	Allzadeh et al., Distinct types of diffuse large B-cell lymphoma identified by gene expressionprofiling. *Nature* 403:503-511 (2000).
	A22	Alt et al., VDJ recombination. *Immunol. Today* 13: 306-314 (1992)
	A23	Anant and Davidson, An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high affinity binding site for APOBEC-1: binding of APOBEC-1 to this motif in the 3' untranslated region of c-myc increase mRNA stability. *Mol Cell. Biol.* 20:1982-92 (2000).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A24	Anant et al., ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. *Am J Physiol Cell Physiol.* 281:C1904-16 (2001).
	A25	Anant et al., Evolutionary origins of the mammalian apolipoprotein B RNA editing enzyme, apobec-1: structural homology inferred from analysis of a cloned chicken small intestinal cytidine deaminase. *Biol Chem.* 379:1075-1081 (1998).
	A26	Anant et al., APOBEC-1 transcription in rat colon cancer: dereased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs. Biochim. Biophys Acta 1571:54-62 (2002).
	A27	Anant et al., APOBEC-1, the catalytic subunit of the mammalian apoB B mRNA editing enzyme, is a novel RNA-binding protein. *J. Biol. Chem.* 270:14762-14767 (1995).
	A28	Anant et al., AU-rich RNA binding proteins Hel-N1 and AUF1 bind apolipoprotein B mRNA and inhibit posttranscriptional C to U editing. *Nucleic Acids Symp. Ser.* 36, 115-118 (1997).
	A29	Anant et al., Molecular mechanisms of apolipoportein B mRNA editing *Curr Opin Lipidol.* 12(2): 159-165 (2001).
	A30	Andersson et al., Temporal expression of a V(H) promoter-Cmu transgene linked to the IgH HS1,2 enhancer. *Mol Immunol.* 36(1):19-29 (1999).
	A31	Arakawa, H., J. Hauschildand J.M. Buerstedde, Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. *Science.* 295(5558):1301-1306 (2002).
	A32	Arulampalam et al., Elevated expression levels of an Ig transgene in mice links the IgH 3' enhancer to the regulation of IgH expression. *Int Immunol* 8(7):1149-1157 (1996).
	A33	Bachl and Wabl, Enhancers of hypermutation. *Immunogenet.* 45: 59-64 (1996).
	A34	Bachl et al., Increased transcription levels induce higher mutation rates in a hypermutating cell line. *J Immunol* 166:5051-5057 (2001).
	A35	Bachl et al., The Ig mutator is dependent on the presence, position, and orientation of the large intron enhancer. *Proc Natl Acad Sci U S A* 95: 2396-2399 (1998).
	A36	Bachl et al.. Hypermutation targets a green fluorescent protein-encoding transgene in the presence of immunoglobulin enhancers. *Eur. J. Immunol.* 29: 1383-1389 (1999).
	A37	Backus and Smith, Apolipoprotein B mRNA sequences 3' of the editing site are necessary and sufficient for editing and editosome assembly. Nucleic Acids Res. 19:6781-6786 (1991).
	A38	Backus and Smith, Specific 3' sequences flanking a minimal apoB mRNA editing 'cassette' are critical for efficient editing in vitro. *Biochim. Biophys. Acta* 1217, 65-73 (1994).
	A39	Backus and Smith, Three distinct RNA sequence elements are required for efficient apoB RNA editing in vitro. *Nucleic Acids Res.* 22, 6007-6014 (1992).
	A40	Backus et al., Only cytidines 5' of the apoB mRNA mooring sequence are edited. *Biochim. Biophys. Acta* 1219:1-14 (1994).
	A41	Backus et al., Quantitation of endogenous liver apolipoprotein B mRNA editing. *Biochem Biophys Res Commun.* 1990 Jul 31;170(2):513-8.
	A42	Barat et al., HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA. *EMB J.* 8(11): 3279-3785 (1989).
	A43	Barbon et al., Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following in vitro neural differentiation. *Brain Res Mol Brain Res.* 2003 Oct 7;117(2):168-78.

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A44	Barchi et al., The decomposition of 1-(.beta.-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) in alkali: mechanism and products. J. Org. Chem.; 1992; 57(2) pp 536 – 541.
	A45	Barchi et al., Improved synthesis of zebularine [1-(beta-D-ribofuranosyl)-dihydropyrimidin-2-one] nucleotides as inhibitors of human deoxycytidylate deaminase. *J Enzyme Inhib* 9:147-162 (1995).
	A46	Baum et al., Apolipoprotein B messenger RNA editing in the rat liver: modulation by fasting and refeeding a high carbohydrate diet. *J. Biol. Chem.* 265, 19263-19270 (1990).
	A47	Berkhout et al., HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. *Science* 292(5514):7 (2001).
	A48	Bernstein et al., The rest is silence. *RNA*. 2001 Nov;7(11):1509-1521.
	A49	Betts et al., Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. *J Mol Biol* 235: 635-656 (1994).
	A50	Betz et al., Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. *Cell* 77: 239-248 (1994).
	A51	Bishop et al., Cytidine deamination of retroviral DNA by divers APOBEC proteins. *Curr Biol.* 2004 Aug 10;14(15): 1392-1396.
	A52	Blanc and Davidson, C-to-U RNA editing: mechanisms leading to genetic diversity. *J. Biol. Chem.* 278: 1395-1398 (2003).
	A53	Blanc et al., Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing. *J Biol Chem.* 2001 Mar 30;276(13):10272-10283.
	A54	Blanc et al., Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity. *J Biol Chem.* 276:46386-46393 (2001).
	A55	Bogerd et al., A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. *Proc Natl Acad Sci USA*. 2004 Mar 16;101(11):3770-3774. Epub 2004 Mar 03.
	A56	Bostrom et al., Apolipoprotein B mRNA editing. Direct determination of the edited base and occurrence in non-apolipoprotein B producing cell lines. *J. Biol. Chem.* 265, 22446-22452 (1990).
	A57	Bouhamdan et al., Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. *J Virol.* 70(2):697-704 (1996).
	A58	Bourara et al., Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. *Science*. 289(5484);1564-1566 (2000).
	A59	Bransteitter et al., Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. *Proc. Natl. Acad. Sci. USA* 100:4102-4107 (2003).
	A60	Bronner et al., Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature* 368: 258-261 (1994).
	A61	Bross et al., DNA Double-Strand Breaks: Prior to but not Sufficient in Targeting Hypermutation. *J Exp Med.* 195(9):1187-1192 (2002).
	A62	Burley, S.K. An overview of structural genomics. *Nature Struct. Biol.* 7:932-934 (2000).
	A63	Bushman, F., A New Cellular System Opposing HIV Infection: Implications for Gene Transfer? *Molecular Therapy.* 6(4):441-442 (October 2002)

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A64	Camaur and Trono, Characterization of Human Immunodeficiency Virus Type 1 Vif Particl Incorporation *J. Virology* 70(9):6106-6111 (1996)
	A65	Carlow, Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: mutation and rescue. *Biochemistry.* 1995 Apr 4;34(13):4220-4224.
	A66	Cartegni et al., Listening to silence and understanding nonsense: exonic mutations that affect splicing. *Nat Rev Genet.* 2002 Apr;3(4):285-298.
	A67	Casellas et al., Ku80 is required for immunoglobulin isotype switching. *Embo J.* 17(8):2404-2411 (1998).
	A68	Casey JL., RNA editing in hepatitis delta virus genotype III requires a branched double-hairpin RNA structure. J Virol. 2002 Aug;76(15):7385-97.
	A69	Cattaneo, R. Biased (A-->I) hypermutation of animal RNA virus genomes. *Curr Opin Genet Dev* 4(6): 895-900 (1994).
	A70	Chan et al., RNA Editing. *Scientific American Science & Medicine.* pp. 68-77 (March/April 1995)
	A71	Chang et al., The molecular genetics of lentiviral vectors--current and future perspectives. *Curr Gene Ther.* 2001 Sept; 1(3):237-51.
	A72	Chaudhuri et al., Transcription-targeted DNA deamination by the AID antibody diversification enzyme. *Nature* 422: 726-730 (2003).
	A73	Chen et al., Alt, RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. *Proc Natl Acad Sci U S A* 90(10):4528-4532 (1993.)
	A74	Chen et al., Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. *Science* 238:363-366(1987).
	A75	Chen et al., Roles of uracil-DNA glycosylase and dUTPase in virus replication. *J Gen Virol.* 83(Pt 10): 2339-2345 (2002).
	A76	Cheng et al., Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J Natl Cancer Inst.* 2003 Mar 5;95(5):399-409.
	A77	Cho et al., Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. *J Biol Chem* 278: 17093-17102 (2003).
	A78	Chothia & Lesk, "The relation between the divergence of sequence and structure in proteins." EMBO J. 1986 Apr; 5(4):823-826.
	A79	Chua et al., The Function of AID in Somatic Mutation and Class Switch Recombination: Upstream or Downstream of DNA Breaks. *J Exp Med.* 195(9):F37-F41 (2002).
	A80	Chuck and Palsson, Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. *Hum Gene Ther* 7: 743-750 (1996).
	A81	Corsetti et al., Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. Atherosclerosis. 2003 Dec;171(2):351-8.
	A82	Courcoul et al., Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. *J Virol.* 1995 Apr; 69(4):2068-2074.
	A83	Damle et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood* 94:1840-1847 (1999).
	A84	Dance et al., APOBEC-1 dependent cytidine to uridine editing of apolipoprotein B RNA in yeast. *Nucleic Acids Res.* 28, 424-429 (2000).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A85	Dance et al., Identification of the yeast cytidine deaminase CDD1 as an orphan C to U RNA editase. *Nucleic Acids Res.* 29,1772-1780 (2001).
	A86	Dance et al., Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. *J. Biol. Chem.* 277:12703-09 (2002).
	A87	Davidson et al., Thyroid hormone modulates the introduction of a stop codon in rat liver apolipoprotein B messenger RNA. *J. Biol. Chem.* 263:13482-13485 (1988).
	A88	Davignon et al., HMG-CoA reductase inhibitors: a look back and a look ahead. *Can J Cardiol.* 8(8):843-864 (October 1992)
	A89	de la Chapelle and Peltomaki, Genetics of hereditary colon cancer. *Annu Rev Genet* 29:329-348 (1995).
	A90	Dettenhofer et al., Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. *J. Virol*, 74(19):8938-8945 (2000).
	A91	Di Noia and Neuberger, Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. *Nature* 419: 43-48 (2002).
	A92	Dickerson et al., AID Mediates Hypermutation by Deaminating Single Stranded DNA. *J Exp Med* 197:1291-1296 (2003).
	A93	Doi et al., Inaugural Article: De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. *Proc natl acad sci USA* 100(5): 2634-2638 (2003).
	A94	Driscoll and Casanova, Characterization of the apolipoprotein B mRNA editing activity in enterocyte extracts. *J Biol Chem.* 265(35): 21401-2143 (1990).
	A95	Driscoll et al., Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. *J Med Chem* 34:3280-3284 (1991).
	A96	Driscoll et al., Induction of RNA editing at heterologous sites by sequences in apolipoprotein B mRNA. *Mol Cell Biol.* 1993 Dec;13(12):7288-7294.
	A97	Durandy, Hyper-IgM syndromes: a model for studying the regulation of class switch recombination and somatic hypermutation generation. *Biochem Soc Trans.* 2002 Aug;30(4):815-818.
	A98	Economidis and Pederson, In vitro assembly of a pre-messenger ribonucleoprotein. P*roc Natl Acad Sci U S A.* 1983 Jul;80(14):4296-4300.
	A99	Egebjerg et al., Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. *Proc. Natl. Acad. Sci. U.S.A.* 91:10270-10274 (1994).
	A100	Ehrenstein et al., Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. *EMBO J.* 18(12):3484-3490 (1999).
	A101	Eliopoulos et al., Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. *Cancer Chemother Pharmacol.* 1998; 42(5):373-8.
	A102	Erbs et al., *In Vivo* Cancer Gene Therapy by Adenovirus-mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene. *Cancer Research.* 3813-3822; July 15, 2000
	A103	Eto et al., RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12895-8. Epub 2003 Oct 14.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A104	Faham and Cox, A novel in vivo method to detect DNA sequence variation. *Genome Res* 5:474-482 (1995).
	A105	Faham et al., Mismatch repair detection (MRD): high-throughput scanning for DNA variations. *Hum Mol Genet.* 2001 Aug 1;10(16):1657-1664.
	A106	Farese et al. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. *Proc. Natl. Acad. Sci. USA.* 93:6393-6398 (1996)
	A107	Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. *Genes Dev* 17: 419-437 (2003).
	A108	Fishel et al., The Human Mutator Gene Homolog MSH2 and its association with Hereditary Nonpolyposis Colon Cancer. *Cell* 75: 1027-1038 (1993).
	A109	Fisher and Pei, Modification of a PCR-Based Site-Directed Mutagenesis Method. *BioTechniques* 23, 570-574 (1997).
	A110	Fisher et al., The *Sor* Gene of HIV-1 is Required for Efficient Virus Transmission in Vitro." Science. 1987 Aug 21;237(4817):888-893.
	A111	Foubister V., Drug reactivates genes to inhibit cancer. *Drug Discov Today.* 2003 May 15;8(10):430-1.
	A112	Frick et al., Binding of Pyrimidin-2-One Ribonucleoside by Cytidine Deaminase as the Transition-State Analogue 3,4-Dihydrouridine and the Contribution of the 4-Hydroxyl Group to its Binding Affinity. *Biochemistry* 28:9423-9430 (1989).
	A113	Fugmann and Schatz, Immunology. One AID to unite them all. *Science.* 295:1244-1245 (2002).
	A114	Funahashi et al., Tissue-specific, developmental and nutritional regulation of the gene encoding the catalytic subunit of the rat apoB mRNA editing enzyme: functional role in the modulation of apoB mRNA editing. *J. Lipid Res.* 36:414-428 (1995).
	A115	Gabay et al., Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. *Eur J Haematol* 63:180-191 (1999).
	A116	Gaddis et al., Comprehensive Investigation of the Molecular Defect in Vif-deficient Human Immunodeficiency Virus Type 1 Virions. *J. Virol.* 77(10): 5810-5820 (2003).
	A117	Gaidano et al., Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood* 102(5):1833-41 (2003)
	A118	GenBank Accession # BC006296
	A119	Genbank Accession # XM_092919
	A120	George CX, Samuel CE. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. *Proc Natl Acad Sci U S A.* 1999 Apr 13;96(8):4621-6.
	A121	Gerber and Keller, RNA editing by base deamination: more enzymes, more targets, new mysteries. *Trends Biochem Sci.* 2001 Jun;26(6):376-384.
	A122	Gerber et al., An Adenosine Deaminase that Generates Inosine at the Wobble Position of tRNAs. *Science* 286(5442): 1146-1149 (1999).
	A123	Giannoni et al., Complementation of Apolipoprotein B mRNA Editing by Human Liver Accompanied by Secretion of Apolipoprotein B48. *J. Biol. Chem.* 269, 5932-5936 (1994).
	A124	Giannoni, et al., Developmental regulation of the catalytic subunit of the apoB mRNA editing enzyme (APOBEC-1) in human small intestine. *J. Lipid Res.* 36, 1664-1675 (1995).

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A125	Goldstein et al., Familial Hypercholesterolemia. *In The Metabolic and Molecular Bases of Inherited Disease*, Scriver et al. (eds), McGraw-Hill, New York, Vol. 2, Chapter 62, pp 1981-2030, (1995)
	A126	Gott and Emeson, Functions and Mechanisms of RNA Editing. *Annu. Rev. Genet.* 34:499-531 (2000).
	A127	Greeve et al., Absence of APOBEC-1 mediated mRNA editing in human carcinomas. *Oncogene* 18:6357-6366 (1999).
	A128	Greeve et al., Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin's lymphomas. *Blood* 101:3574-3580 (2003).
	A129	Greeve et al., Inhibition of the Apolipoprotein B mRNA Editing Enzyme-Complex by hnRNP C1 Protein and 40S hnRNP Complexes. Biol. Chem. 379:063-1073 (1998).
	A130	Greeve, et al., Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. *J. Lipid Res.* 34:1367-1383 (1993).
	A131	Gulick et al., Rayment I. X-Ray Structures of the Dictyostelium Discoideum Myosin Motor Domain with Six Non-Nucleotide Analogs. *J Biol Chem.* 2000 Jan 7; 275(1):398-408.
	A132	Hamblin et al., Unmutated Ig V(H) Genes Are Associated with a More Aggressive Form of Chronic Lymphocytic Leukemia. *Blood* 94:1848-1854 (1999).
	A133	Harris and Smith, In Vitro ApoB mRNA Editing Activity Can Be Modulated By Fasting and Refeeding Rats With A High Carbohydrate Diet. *Biochem. Biophys. Res. Commun.* 183:899-903 (1992).
	A134	Harris et al., DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. *Nature Immunology* 641-643 (2003)
	A135	Harris et al., DNA Deamination Mediates Innate Immunity to Retroviral Infection. *Cell.* 2003 Jun 13;113(6):803-809.
	A136	Harris et al., Extract-Specific Heterogeneity in High-Order Complexes Containing Apolipoprotein B mRNA Editing Activity and RNA-Binding Pproteins. *J Biol Chem.* 1993 Apr 5;268(10):7382-7392.
	A137	Harris et al., RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutator. *Mol. Cell* 10(5): 1247-1253 (2002).
	A138	Henzler et al., Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure, *J Gen Virol.* 2001 Mar ;82(Pt 3):561-573.
	A139	Hersberger and Innerarity, Two Efficiency Elements Flanking the Editing Site of Cytidine 6666 in the Apolipoprotein B mRNA Support Mooring-Dependent Editing. *J. Biol. Chem.* 273, 9435-9442 (1998).
	A140	Hersberger et al., Phylogenetic Analysis of the Apolipoprotein B mRNA-Editing Region. Evidence for a secondary structure between the mooring sequence and the 3' efficiency element. *J. Biol. Chem.* 274, 34590-34597 (1999).
	A141	Higuchi et al., "RNA Editing of AMPA Receptor Subunit GluR-B: A Base-Paired Intron-Exon Structure Determines Position and Efficiency." Cell. 1993 Dec 31;75(7):1361-1370
	A142	Higuchi et al., Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. *Nature* (London) 405, 78-81 (2000).
	A143	Hilleren and Parker, mRNA surveillance in eukaryotes: Kinetic proofreading of proper translation termination as assessed by mRNP domain organization? *RNA* 5(6): p. 711-719 1999).
	A144	Hirano et al., Targeted Disruption of the Mouse Apobec-1 Gene Abolishes AapoB mRNA Editing and Eliminates ApoB48. *J. Biol. Chem.* 271, 9887-9890 (1996).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A145	Holladay et al., Synthesis of Hydroxyethlene and Ketomethylene Dipeptide Isosteres, *Tetrahedron. Lett* 24:4401-4404 (1983)
	A146	Honjo et al., Molecular Mechanism of Class Switch Recombination: Linkage with Somatic Hypermutation. *Annu Rev Immunol.* 20:165-196 (2002).
	A147	Honjo, Immunoglobulin Genes. *Annu Rev Immunol.* 1983; 1:499-528.
	A148	Hu et al., Telomerase Is Up-Regulated in Human Germinal Center B Cells In Vivo and Can Be Re-expressed in Memory B Cells Activated in Vitro. *J Immunol* 159(3):1068-1071 (1997).
	A149	Hughes et al., Gene Transfer of Cytidine Deaminase apoBEC-1 Lowers Lipoprotein(a) In Transgenic Mice and Induces Apolipoprotein B mRNA Editing in Rabbits. *Hum. Gene Ther.* 7:39-49 (January 1, 1996)
	A150	Hung et al., dsRBM1 and a proline-rich domain of RNA helicase A can form a composite binder to recognize a specific dsDNA. *Nucleic Acids Res.* 2003 Oct 1; 31(19):5741-53.
	A151	Inui et al., REPR and complementation factor(s) interact to modulate rat apolipoprotein B mRNA editing in response to alterations in cellular cholesterol flux. *J. Lipid Res.* 35, 1477-1489 (1994).
	A152	Itakura et al., Synthesis and Use of Synthetic Oligonucleotides. *Annu Rev Biochem.* 1984; 53:323-56.
	A153	Jansen and Zangemeister-Wittke, Antisense therapy for cancer -- the time of truth. *Lancet Oncol* 3: 672-683 (2002).
	A154	Jarmuz et al., An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22. *Genomics.* 2002 Mar; 79(3):285-296.
	A155	Jayan GC and Casey, JL, Increased RNA Editing and Inhibition of Hepatitis Delta Virus Replication by High-Level Expression of ADAR1 and ADAR2. *J Virol.* 2002 Apr.; 3819-3827.
	A156	Jayan GC and Casey JL., Inhibition of Hepatitis Delta Virus RNA Editing by Short Inhibitory RNA-Mediated Knockdown of ADAR1 but not ADAR2 Expression. *J Virol.* 2002 Dec; 76(23):12399-404.
	A157	Johansson et al., Crystal Structure of the Tetrameric Cytidine Deaminase from Bacillus Subtilis at 2.0 Å Resolution. *Biochem.* 41 2563-2570 (2002).
	A158	Johnson et al., The Mechanism for Apo-B mRNA Editing is Deamination. *Biochem Biophys Res Commun.* 1993 Sep 30; 195(3):1204-1210.
	A159	Jones et al., Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in these Models. *Acta Crystallogr A.* 1991 Mar 1; 47 (Pt 2):110-119.
	A160	Juliano and Yoo, Aspects of the transport and delivery of antisense oligonucleotides. *Curr Opin Mol Ther* 2:297-303 (2000).
	A161	Kabsch, *W Acta. Crystallogr.* (1976) A32: p. 922-923
	A162	Kataoka et al., Pre-mRNA Splicing Imprints mRNA in the Nucleus with a Novel RNA-Binding Protein that Persists in the Cytoplasm. *Mol Cell.* 2000 Sep; 6(3):673-682.
	A163	Kaushik et al., PNA targeting the PBS and A-loop Sequences of HIV-1 Genome Destabilizes Packaged tRNA3(Lys) in the Virions and Inhibits HIV-1 Replication. *Virology.* 303(2): 297-308 (2002).
	A164	Keegan et al., The Many Roles of an RNA Editor. *Nat Rev Genet.* 2001 Nov; 2(11):869-878.
	A165	Keegan et al., The Properties of a tRNA-Specific Adenosine Deaminase from Drosophila Melanogaster Support an Evolutionary Link Between Pre-mRNA Editing and tRNA Modification. *Mol Cell Biol* 20(3): 825-833 (2000).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/523,038
	Intl. Filing Date	8/5/2003
	First Named Inventor	Smith, H., *et al.*
	Group Art Unit	1648
	Examiner Name	Unassigned

	A166	Keller et al., Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. *FEBS Lett*, 452(1-2): 71-76. (1999)
	A167	Kelley et al., Furanose-Pyranose Isomerization of Reduced Pyrimidine and Cyclic Urea Ribosides. *J Med Chem.* 1986 Nov; 29(11):2351-8.
	A168	Khamlichi et al., The 3' IgH Regulatory Region: A Complex Structure in a Search for a Function. *Adv Immunol* 75: 317-345 (2000).
	A169	Khan et al., Human Immunodeficiency Virus Type 1 Vif Protein Is Packaged into the Nucleoprotein Complex through an Interaction with Viral Genomic RNA. *J Virol.* 2001 Aug; 75(16):7252-7265.
	A170	Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. *J Med Chem.* 1986 Aug; 29(8):1374-80.
	A171	Kinoshita and Honjo, Unique and unprecedented recombination mechanisms in class switching. *Curr. Opin. Immunol.* 12: 195-198 (2000).
	A172	Kleiman, L., tRNA(Lys3): The Primer tRNA for Reverse Transcription in HIV-1. *IUBMB Life* 53(2): 107-114 (2002).
	A173	Kohler et al., Determinants of Ca2+ Permeability in Both TM1 and TM2 of High Affinity Kainate Receptor Channels: Diversity by RNA Editing. *Neuron.* 1993 Mar; 10(3):491-500.
	A174	Kong and Maizels, DNA Breaks in Hypermutating Immunoglobulin Genes: Evidence for a Break-and-Repair Pathway of Somatic Hypermutation. *Genetics* 158:369-378 (2001).
	A175	Kong et al., Recombination-based mechanisms for somatic hypermutation. *Immunol Rev* 162: 67-76 (1998).
	A176	Kozarsky et al., Hepatic Expression of the Catalytic Subunit of the Apolipoprotein B mRNA Editing Enzyme (*apobec-1*)Ameliorates Hypercholesterolemia in LDL Receptor-Deficient Rabbits. *Hum. Gene Ther.* 7:943-957 (May 20, 1996)
	A177	Krogh et al., Hidden Markov Models in Computational Biology. Applications to Protein Modeling, *J Mol Biol.* 235, 1501-1531 (1994).
	A178	Kumar et al., Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. *Proc Natl Acad Sci USA.* 94(8): 3542-3547 (1997).
	A179	Kuyper, LF, et al., Resolving crystal polymorphisms by finding "stationary points" from quantitative analysis of crystal growth response surfaces, *J. Crystal Growth,* 168: p. 155-169(1996)
	A180	Kuzin et al., Tetracyclines inhibit activated B cell function. *Int. Immunol.* 12: 921-931 (2001).
	A181	Kuzin et al., Normal Isotype Switching in B cells Lacking the Iμ Exon Splice Donor Site: Evidence for Multiple Iμ-Like Germline Transcripts. *J Immunol.* 2000 Feb 1; 164(3):1451-1457.
	A182	Laliberte et al., Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. *Cancer Chemother Pharmacol.* 1992; 30(1):7-11.
	A183	Lambert et al., Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev. 2001 Mar 23;47(1):99-112.
	A184	Laskowski et al., *J. Applied Crystallography.* 1993;26:283-291
	A185	Lau et al., A DnaJ protein, Apobec-1-Binding Protein-2, Modulates Apolipoprotein B MRNA Editing. *J. Biol. Chem.* 275:46445-46452 (2001).
	A186	Lau et al., Apolipoprotein B mRNA Editing is an Intranuclear Event that Occurs Posttranscriptionally Coincident with Splicing and Polyadenylation. *J Biol Chem.* 1991 Oct 25; 266(30):20550-20554.

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A187	Lau et al., Cloning of an Apobec-1-Binding Protein that also Interacts with Apolipoprotein B mRNA and Evidence for Its Involvement in RNA Editing. *J Biol Chem.* 1997 Jan 17; 272(3):1452-1455.
	A188	Lau et al., Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. *Proc Natl Acad Sci U S A.* 1994 Aug 30; 91(18):8522-8526.
	A189	Lau et al., Ethanol modulates apolipoprotein B mRNA editing in the rat. *J Lipid Res.* 1995 Oct; 36(10):2069-2078.
	A190	Lau et al., Two-Hybrid Cloning Identifies an RNA-Binding Protein, GRY-RBP, as a Component of Apobec-1 Editosome. *Biochem Biophys Res Commun.* 2001 Apr 13; 282(4):977-983.
	A191	Le Hir et al., The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. *EMBO J.* 19:6860-6869 (2000).
	A192	Lecossier, et al., Hypermutation of HIV-1 DNA in the Absence of the Vif Protein. *Science.* 300(5622): 1112 (2003).
	A193	Lee et al., An Alternatively Spliced Form of Apobec-1 Messenger RNA is Overexpressed in Human Colon Cancer. *Gastroenterology.* 1998 Nov; 115(5):1096-1103.
	A194	Lee et al., Transduction of yeast cytosine deaminase medicated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine. *Experimental and Molecular Medicine*, 2004 Feb., 43-51.
	A195	Lehmann KA, Bass BL. The Importance of Internal Loops within RNA Substrates of ADAR1. *J Mol Biol.* 1999 Aug 6; 291(1):1-13.
	A196	Lellek et al., Purification and Molecular Cloning of a Novel Essential Component of the Apolipoprotein B mRNA Editing Enzyme-Complex. *J Biol Chem.* 2000 Jun 30; 275(26):19848-19856.
	A197	Lesk and Chothia, How Different Amino Acid Sequences Determine Similar Protein Structures: The Structure and Evolutionary Dynamics of the Globins. *J Mol Biol.* 1980 Jan 25; 136(3):225-270.
	A198	Lewis and Tollervey, Like Attracts Like: Getting RNA Processing Together in the Nucleus. *Science.* 2000 May 26; 288(5470):1385-1389.
	A199	Liao et al., APOBEC-2, A Cardiac- and Skeletal Muscle-Specific Member of the Cytidine Deaminase Supergene Family. *Biochem Biophys Res Commun.* 1999 Jul 5; 260(2):398-404.
	A200	Liu et al., Influence of Primate Lentiviral Vif and Proteasome Inhibitors on Human Immunodeficiency Virus Type 1 Virion Packaging of APOBEC3G. J Virol. 2004 Feb; 78(4):2072-81.
	A201	Liu et al., A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. *Nat Genet.* 2001 Jan;27(1):55-58.
	A202	Liu et al., Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. *Genes Dev.* 12(13):1998-2012 (1998).
	A203	Liu et al., Mechanism of Interferon Action: Functionally Distinct RNA-Binding and Catalytic Domains in the Interferon-Inducible, Double-Stranded RNA-Specific Adenosine Deaminase. *J. Virol.* 70(3):1961-1968 (1996).
	A204	Liu et al., Serotonin-2C Receptor Pre-mRNA Editing in Rat Brain and *In Vitro* by Splice Site Variants of the Interferon-Inducible, Double-Stranded RNA-Specific Adenosine Deaminase ADAR1. *J. Biol Chem.* 274(26): 18351-18358 (1999).
	A205	Liu et al., The Vif Protein of Human and Simian Immunodeficiency Viruses is Packaged into Virions and Associates with Viral Core Structures. *J. Virol.* 69(12): 7630-7638 (1995).
	A206	Loeb et al., Multiple mutations and cancer. *Proc Natl Acad Sci U S A* 100:776-781 (2003)

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A207	Loeb, A Mutator Phenotype in Cancer. *Cancer Res.* 2001 Apr 15; 61(8):3230-3239.
	A208	Loeb, Mutator Phenotype May Be Required for Multistage Carcinogenesis. *Cancer Res* 51:3075-3079 (1991).
	A209	Logan AC, Lutzko C, Kohn DB., Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. *Curr Opin Biotechnol.* 2002 Oct;13(5):429-36.
	A210	Longacre and Storb, A Novel Cytidine Deaminase Affects Antibody Diversity. *Cell.* 102(5): p. 541-544 (2000).
	A211	Lossos et al., Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. *Proc. Natl. Acad. Sci. USA* 97:10209-10213 (2000).
	A212	Maas and Rich, Changing genetic information through RNA editing. *BioEssays* 22, 790-802 (2000).
	A213	Maas et al., Mammalian RNA-dependent deaminases and edited mRNAs. *Curr Opin Cell Biol.* 1997 Jun; 9(3):343-349
	A214	Maas et al., Structural Requirements for RNA Editing in Glutamate Receptor Pre-mRNAs by Recombinant Double-Stranded RNA Adenosine Deaminase. *J Biol Chem.* 1996 May 24; 271(21):12221-12226.
	A215	MacGinnitie et al., Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. *J Biol Chem.* 1995 Jun 16;270(24):14768-14775.
	A216	Machida et al., Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobin and protooncogenes. *Proc Natl Acad Sci USA.* 101(12):4262-4267. (2004).
	A217	MacKerell et al., All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins, *J. Phys. Chem. B.* 1998;102:3586-3616
	A218	Madani and Kabat, An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes is Overcome by the Viral Vif Protein. *J Virol.* 1998 Dec; 72(12):10251-10255.
	A219	Madsen et al., Psoriasis Upregulated Phorbolin-1 Shares Structural but not Functional Similarity to the mRNA-Editing Protein Apobec-1. *J Invest Dermatol.* 1999 Aug; 113(2):162-169.
	A220	Mangeat et al., Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature.* Advance online publication , in press (2003) pp. 99-103
	A221	Manis et al., Ku70 is Required for Late B Cell Development and Immunoglobulin Heavy Chain Class Switching. *J Exp Med.* 187(12):2081-2089 (1998).
	A222	Manis et al., Mechanism and control of class-switch recombination. *Trends Immunol* 23: 31-39 (2002).
	A223	Mansky et al., The Interaction of vpr with Uracil DNA Glycosylase Modulates the Human Immunodeficiency Virus Type 1 *In Vivo* Mutation Rate.*J. Virol.* 74(15):7039-7047 (2000)
	A224	Maquat and Carmichael, Quality Control of mRNA Function. *Cell.* 2001 Jan 26; 104(2):173-176.
	A225	Mariani et al., Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif. *Cell.* 114(1):21-31. (2003)
	A226	Martin and Scharff, AID and Mismatch Repair in Antibody Diversification. *Nat Rev Immunol.* 2002 Aug;2(8):605-614.
	A227	Martin et al., Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. *Nature.* 2002 Feb 14; 415(6873):802-806.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A228	Mathews and Turner, Dynalign: An Algorithm for Finding the Secondary Structure Common to Two RNA Sequences. *J Mol Biol* 317: 191-203 (2002).
	A229	McCahill et al., Acute modulation of the extent of apoB mRNA editing and relative rates of synthesis of apoB48 and apoB100 in cultured rat hepatocytes by osmotic and other stress stimuli. *Molec. Cell. Biochem.* 208:77-87 (2000).
	A230	McCarthy et al., High Expression of Activation-Induced Cytidine Deaminase (AID) and Splice Variants is a Distinctive Feature of Poor Prognosis Chronic Lymphocytic Leukemia. *Blood* 101(12):4903-8 (2003)
	A231	Medical Research Council. Innate defence against HIV infection understood. http://ww.mrc.ac.uk (May 29, 2003).
	A232	Mehta and Driscoll, Identification of domains in apobec-1 complementation factor required for RNA binding and apolipoprotein-B mRNA editing. *RNA.* 2002 Jan;8(1):69-82.
	A233	Mehta et al., Molecular Cloning of Apobec-1 Complementation Factor, A Novel RNA-Binding Protein Involved in the Editing of Apolipoprotein B mRNA. *Mol Cell Biol.* 2000 Mar; 20(5):1846-1854.
	A234	Meyer et al., High rate of somatic point mutation in vitro in and near the variable-region segment of an immunoglobulin heavy chain gene. *Proc Natl Acad Sci U S A* 83:6950-6953 (1986)
	A235	Mian et al., Statistical Modelling and Phylogenetic Analysis of a Deaminase Domain. *J Comput Biol.* 1998 Spring; 5(1):57-72.
	A236	Minegishi et al., Mutations in Activation-Induced Cytidine Deaminase in Patients with Hyper IgM Syndrome. *Clin Immunol.* 97:203-210 (2000).
	A237	Morrison et al., ApoB RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism. *Proc. Natl. Acad. Sci. USA* 93, 7154-7159 (1996).
	A238	Moss, et. Al., Thrombogenic Factors and Recurrent Coronary Events. *Circulation.* 1999 May 18; 99(19):2517-22.
	A239	Mukhopadhyay et al., C-->U Editing of Neurofibromatosis 1 mRNA Occurs in Tumors that Express Both the Type II Transcript and Apobec-1, the Catalytic Subunit of the Apolipoprotein B mRNA-Editing Enzyme. *Am J Hum Genet.* 70(1):38-50 (2002).
	A240	Muramatsu et al., Specific Expression of Activation-Induced Cytidine Deaminase (AID), a Novel Member of the RNA-Editing Deaminase Family in Germinal Center B Cells. *J. Biol. Chem.* 274: 18470-18476 (1999).
	A241	Muramatsu et al., Class Switch Recognition and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme. *Cell* 102, 553-564 (2000).
	A242	Muschen et al. Somatic Mutation of the CD95 Gene in Human B Cells as a Side-Effect of the Germinal Center Reaction. *J Exp Med* 192:1833-1840 (2000).
	A243	Muschen et al., The origin of CD95-gene mutations in B-cell lymphoma. *Trends Immunol.* 23(2):75-80 (2002).
	A244	Muto et al., Isolation, Tissue Distribution, and Chromosomal Localization of the Human Activation-Induced Cytidine Deaminase (AID) Gene. *Genomics* 68(1): 85-88 (2000)
	A245	Nagahara et al., Transduction of full-length TAT fusion proteins into mammalian cells: TAT-$p27^{Kip1}$ induces cell migration. *Nat. Med.* 4(12):1449-1452 (December 1998)
	A246	Nagaoka et al., Activation-Induced Deaminase (AID)-Directed Hypermutation in the Immunoglobulin Sμ Region: Implication of AID Involvement in a Common Step of Class Switch Recombination and Somatic Hypermutation. *J Exp Med*, 195(4): p. 529-534 (2002).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A247	Nakamuta et al., Complete Phenotypic Characterization of Apobec-1 Knockout Mice with a Wild-Type Genetic Background and a Human ApoB Transgenic Background, and Restoration of ApoB mRNA Editing by Somatic Gene Transfer of APOBEC-1. *J. Biol. Chem.* 271:25981-25988 (1996).
	A248	Navaratnam et al., An additional editing site is present in apolipoprotein B mRNA. *Nucleic Acids Res.* 19:1741-1744 (1991).
	A249	Navaratnam et al., Apolipoprotein B mRNA editing is associated with UV crosslinking of proteins to the editing site. *Proc Natl Acad Sci U S A.* 90(1): 222-226 (1993).
	A250	Navaratnam et al., Escherichia Coli Cytidine Deaminase Provides a Molecular Model for ApoB RNA Editing and a Mechanism for RNA Substrate Recognition *JMB* 275:695-714 (1998).
	A251	Navaratnam et al., Evolutionary Origins of ApoB mRNA Editing: Catalysis by a Cytidine Deaminase that has Acquired a Novel RNA-Binding Motif at Its Active Site. *Cell* 81:187-195 (1995).
	A252	Neuberger et al., Monitoring and interpreting the intrinsic features of somatic hypermutation. *Immunol Rev* 162:107-116 (1998).
	A253	Neuberger et. al., Immunity through DNA deamination. Trends Biochem Sci. 2003 Jun;28(6):305-12.
	A254	Neuhard, J., Pyrimidine Nucleotide Metabolism and Pathways of Thymidine Triphosphate Biosynthesis in Salmonella Typhimurium. Journal of Bacteriolgy, 1968. 96(5): p. 1519-1527
	A255	Neumann et al., A Novel Rapid Assay for Chloramphenicol Acetyltransferase Gene Expression. *BioTechniques* 5:444-448 (1987).
	A256	Nicolaides et al., Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* 371: 75-80 (1994).
	A257	O'Connell, RNA Editing: Rewriting Receptors. *Current Biology* 7:R437-R439 (1997).
	A258	Ohagen et al., Role of Vif in Stability of the Human Immunodeficiency Virus Type 1 Core. *J Virol,*. 74(23):11055-11066 (2000)
	A259	Oka et al., Tissue-Specific Inhibition of ApoB B mRNA Editing in the Liver by Adenovirus-Mediated Transfer of a Dominant Negative Mutant APOBEC-1 Leads to Increased Low Density Lipoprotein in Mice. *J. Biol. Chem.* 272, 1456-1460 (1997).
	A260	Okazaki et al., Constitutive Expression of AID Leads to Tumorigenesis. *J. Exp. Med.* 197:1173-1181 (2003).
	A261	Okazaki et al., The AID enzyme induces class switch recombination in fibroblasts. *Nature*. 416:340-345 (2002)
	A262	Oppezzo et al., Chronic lymphocytic leukemia B cells expressing AID display a dissociation between class switch recombination and somatic hypermutation. *Blood* 101(10):4029-32 (2003).
	A263	Paddison et al., Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev.* 16(8):948-958 (2002).
	A264	Paddison et al., Stable suppression of gene expression by RNAi in mammalian cells. *Proc Natl Acad Sci U S A* 99(3):1443-1448 (2002).
	A265	Papadopoulos et al., Mutation of a mutL Homolog in Hereditary Colon Cancer. *Science* 263: 1625-1629 (1994).
	A266	Papavasiliou and Schatz, Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. *Nature* 408(6809):216-221 (2000).
	A267	Papavasiliou and Schatz, The Activation-induced Deaminase Functions in a Postcleavage Step of the Somatic Hypermutation Process. *J Exp Med* 195(9):1193-1198 (2002).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A268	Pasqualucci et al., BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci U S A* 95:11816-11821 (1998).
	A269	Pasqualucci et al., Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature* 412: 341-346 (2001).
	A270	Pasqualucci et al., Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood* 101:2914-2923 (2003).
	A271	Pear et al., Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-transduced Bone Marrow. *Blood* 92: 3780-3792 (1998).
	A272	Petersen-Mahrt and Neuberger, 2003. *In vitro* Deamination of Cytosine to Uracil in Single-Stranded DNA by APOBEC1. *J. Biol. Chem.* in press (2003).
	A273	Petersen-Mahrt et al., AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. *Nature.* 2002 Jul 4;418(6893):99-103.
	A274	Pham et. al., Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. *Nature.* 2003 Jul 3;424(6944):103-7.
	A275	Phung et al., Regulation of Hepatic ApoB RNA Editing in the Genetically Obese Zucker Rat. *Metabolism* 45:1056-1058 (1996
	A276	Polson et al., RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. *Nature* 380(6573):454-456 (1996).
	A277	Potterton, The CCP4 molecular-graphics project, *Acta Crystallogr D Biol Crystallogr,* (2002) 58(Pt 11): p. 1955-7
	A278	Powell et al., A Novel Form of Tissue-Specific RNA Processing Produces Apolipoprotein-B48 in Intestine. *Cell* 1996;50:831-840
	A279	Puck, A Disease Gene for Autosomal Hyper-IgM Syndrome: More Genes Associated with More Immunodeficiencies. *Clin Immunol.* 2000;97(3):191-192
	A280	Qian et al., Low Expression of the Aplolipoprotein B mRN A-Editing Transgene in Mice Reduces LDL Level but Does Not Cause Liver Dysplasia or Tumors. *Arterioscler. Thromb. Vasc. Biol.* 1998;18:1013-1020 (
	A281	Rabinovici et. al., ADAR1 Is Involved in the Development of Microvascular Lung Injury. *Circ Res.* 2001 May 25; 88(10):1066-71.
	A282	Rada et al. AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization. *Proc. Natl. Acad. Sci USA.* 2002;99(10):7003-7008
	A283	Rada et al., Immunoglobulin Isotype Switching is Inhibited and Somatic Hypermutation Perturbed in UNG-Deficient Mice. *Curr. Biol.* 12: 1748-1755 (2002).
	A284	Ramiro et al., Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. *Nat Immunol.* 2003 May;4(5):452-6.
	A285	Renda et al., Mutation of the Methylated tRNA(Lys)(3) Residue A58 Disrupts Reverse Transcription and Inhibits Replication of Human Immunodeficiency Virus Type 1. *J Virol* 75(20):9671-8 (2001).
	A286	Revy et al., Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2). *Cell* 2000;102(5):565-576
	A287	Richardson et al., Secondary Structure for the Apolipoprotein B mRNA Editing Site. AU Binding Proteins Interact with a Stem Loop. *J. Biol Chem.* 1998;273:31707-31717

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A288	Rodriguez et. al., DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection are Rectified by Ubiquitination. *J Virol.* 1998 72(6):5174-81.
	A289	Rolink et al., The SCID but not the RAG-2 Gene Product is Required for S mu-S Epsilon Heavy Chain Class Switching. *Immunity* 1996;5(4):319-330
	A290	Rosenwald et al., Lymphoma/Leukemia Molecular Profiling Project. The Use of Molecular Profiling to Predict Survival After Chemotherapy for Diffuse Large-B-Cell Lymphoma. *N Engl J Med.* 2002 Jun 20; 346(25):1937-47.
	A291	Rueter et al., Adenosine-to-Inosine Conversion in mRNA, Modification and Editing of RNA (Grosjean, H. and Benne, R., eds.), 19:343-361, American Society for Microbiology Press, Washington (1998).
	A292	Rueter et al. Regulation of Alternative Splicing by RNA Editing." *Nature.* 399(6731):75-80 (1999)
	A293	Sakashita and Sakamoto, Protein-RNA and Protein-Protein Interactions of the Drosophila Sex-Lethal Mediated by its RNA-Binding Domains. *Journal of Biochemistry* 1996;120(5):1028-1033
	A294	Sale et al., Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. *Nature.* 2001;412(6850):921-926
	A295	Sali and Blundell, Comparative Protein Modelling by Satisfaction of Spatial Restraints, *J. Mol. Biol.* 1993;234:779-815
	A296	Sato et al., Hepatitis Delta Virus Minimal Substrates Competent for Editing by ADAR1 and ADAR2. *J Virol.* 2001 Sep;75(18):8547-55.
	A297	Scadden AD, Smith CW. RNAi is antagonized by A-->I hyper-editing. *EMBO Rep.* 2001 Dec;2(12):1107-11.
	A298	Scadden AD, Smith CW. Specific cleavage of hyper-edited dsRNAs. *EMBO J.* 2001 Aug 1;20(15):4243-52.
	A299	Schlissel et al., Virus-Transformed Pre-B Cells Show Ordered Activation but not Inactivation of Immunoglobulin Gene Rearrangement and Transcription. *J. Exp. Med.* 1991;173:711-720
	A300	Schock et al., An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing. *Proc Natl Acad Sci U S A.* 1996 Feb 6;93(3):1097-1102
	A301	Schrader et al., Reduced Isotype Switching in Splenic B Cells from Mice Deficienct in Mismatch Repair. *J. Exp. Med.* 1999;190: 323-330
	A302	Schrader et al., Role for Mismatch Repair Proteins Msh2, Mlh1, and Pms2 in Immunoglobulin Class Switching Shown by Sequence Analysis of Recombination Junctions. *J. Exp. Med.* 2002;195: 367-373
	A303	Schwartz and Zhang, Peptide-mediated cellular delivery. *Current Opinion in Molecular Therapeutics.* (2000)
	A304	Schwarze et al. In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. *Science.* 285:1569-1572 (September 3, 1999)
	A305	Schwarze et al. *In vivo* protein transduction: intracellular delivery of biologically active proteins, compounds, and DNA. *TiPS.* 21:45-48 (February 2000)
	A306	Schwarze et al. Protein transduction: unrestricted delivery into all cells. *Trends Cell Biol.* 10:290-295 (July 2000)
	A307	Scott, The Molecular and Cell Biology of Apolipoprotein-B..*J. Mol. Med.* 1989;6:65-80

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A308	Seeburg et al., RNA editing of brain glutamate receptor channels: mechanism and physiology. *Brain Res Brain Res Rev.* 1998 May;26(2-3):217-29.
	A309	Selig et al., Uracil DNA Glycosylase Specifically Interacts with Vpr of Both Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus of Sooty Mangabeys, but Binding does not Correlate with Cell Cycle Arrest. *J Virol.* 71(6):4842-4846. (1997)
	A310	Shah et al., Sequence Requirements for the Editing of Apolipoprotein B mRNA. *J. Biol. Chem.* 1991;266:16301-16304
	A311	Sheehy et al., The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. *Nat Med.* 2003 Nov;9(11):1404-7.
	A312	Sheehy et al., Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature.* 2002;418:646-650
	A313	Shen et al., Mutation of BCL-6 Gene in Normal B Cells by the Process of Somatic Hypermutation of Ig Genes. *Science* 1998;280:1750-1752
	A314	Shinkura et al., The influence of transcriptional orientation on endogenous switch region function. *Nat Immunol* 2003;4: 435-441
	A315	Siddiqui et al., Disproportionate Relationship Between APOBEC-1 Expression and Apolipoprotein B mRNA Editing Activity. Exp. *Cell Res.* 1999;252:154-164
	A316	Simon et al., The Human Immunodefiency Virus Type I Vif Protein Modulates the Postpenetration Stability of Viral Nucleoprotein Complexes, *J. Virol.* 1996;70(8):5297-5305
	A317	Simon et al., Evidence for a newly discovered cellular anti-HIV-1 phenotype, *Nat Med* 4(12):1397-1400
	A318	Simpson and Emeson, RNA Editing. *Annu. Rev. Neurosci.* 1996;19:27-52
	A319	Skuse et al., The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. *Nucleic Acids Res.* 1996; 24(3):478-486
	A320	Smith and Sowden, Base Modification RNA Editing through Deamination – the Good, the Bad and the Unregulated. *Trends in Genetics* 1996;12:418-424
	A321	Smith et al., A guide to RNA editing. *RNA* 1997; 3:1105-1123
	A322	Smith et al.,. In vitro Apolipoprotein B mRNA editing: identification of a 27 S editing complex. *Proc. Natl. Acad. Sci. U.S.A.* 1991; 88:1489-1493
	A323	Smith, Analysis of Protein Complexes Assembled On apolipoprotein B mRNA for Mooring Sequence-Dependent RNA Editing. *Methods.* 1998 May; 15(1):27-39.
	A324	Smith, Apolipoprotein B mRNA editing: the sequence to the event. Seminars in Cell Biology (Stuart, K., ed.) Saunders Sci. Publications/Academic Press, London, 4, 267-278 (1993).
	A325	Sohail et al., Human activation-induced cytidine deaminase causes transcript-dependent, strand-biased C to U deaminations. *Nucleic Acids. Res.* 31(12):2990-2994 (2003)
	A326	Sova et al., Efficiency of Viral DNA Synthesis During Infection of Permissive and Nonpermissive Cells with *vif*-Negative Human Immunodeficiency Virus Type 1. *J Virol.* 67(10): 6322-6 (1993)
	A327	Sowden and Smith, Commitment of apolipoprotein B RNA to the splicing pathway regulates cytidine-to-uridine editing-site utilization. *Biochem J* 2001; 359(Pt 3):697-705
	A328	Sowden et al., Apolipoprotein B RNA sequence 3' of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing. *Nucleic Acids Res.* 26, 1644-1652 (1998).

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A329	Sowden et al., Determinants involved in regulating the proportion of edited apolipoprotein B RNAs. *RNA* 1996; 2:274-288
	A330	Sowden et al., Multiple Cooperative Interactions Constrain BPV-1 E2 Dependent Activation of Transcription. *Nucleic Acids Res.* 1989;17:2959-2972
	A331	Sowden et al., Over-Expression of APOBEC-I Results in Mooring Sequence Dependent Promiscuous RNA Editing. J. Biol. Chem. 1996;271:3011-3017
	A332	Sowden et al., The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. *J. Cell Science* 2002;115:1027-1039
	A333	Sparks et al., Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. *Biochem. J.* 313:567-574 (1996)
	A334	Spector, Macromolecular Domains within the Cell Nucleus. *Annu. Rev. Cell Biol.* 1993;9:265-315
	A335	Steinburg et al., Tissue-Specific Differences in the Role of RNA 3' of the Apolipoprotein B mRNA Mooring Sequence in Editosome Assembly. *Biochem. Biophys. Res. Commun.* 1999;263:81-86
	A336	Stopak et al. HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both its Translation and Intracellular Stability. *Mol Cell.* 12(3):591-601 (2003)
	A337	Storb et al., Cis-acting sequences that affect somatic hypermutation of Ig genes. *Immunol Rev* 1998;162: 153-160
	A338	Strasser et al., The Role of bcl-2 in Lymphoid Differentiation and Neoplastic Transformation. *Curr Top Microbiol Immunol* 1992;182:299-302
	A339	Strauss. Introducing Proteins into the Body's Cells. *Science.* 285:1466-1467 (1999)
	A340	Strebel, et al., The HIV 'A' (*sor*) gene product is essential for virus infectivity, *Nature*; 328(6132):728-730 (1987)
	A341	Stull et al., Simultaneous Flow Cytometric Analyses of Enhanced Green and Yellow Fluorescent Proteins and Cell Surface Antigens in Doubly Transduced Immature Hematopoietic Cell Ppopulations. *Cytometry* 2000; 40:126-134
	A342	Taagepera et al., Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. *Proc. Natl. Acad. Sci. U.S.A.* 1998; 95:7457-7462
	A343	Tashiro et al., Palindromic but not G-rich sequences are targets of class switch recombination. Int. Immunol. 2001; 13:495-505
	A344	Teng and Davidson, Evolution of Intestinal Apolipoprotein B mRNA Editing. Chicken Apolipoprotein B mRNA is not Edited, but Chicken Enterocytes Contain in Vitro Editing Enhancement Factor(s). *J Biol Chem.* 1992; 267(29):21265-21272
	A345	Teng et al., Effective Lowering of Plasma, LDL, and Esterified Cholesterol in LDL Receptor-Knockout Mice by Adenovirus-Mediated Gene Delivery of ApoB mRNA Editing Enzyme (Apobec 1). *Arterioscler. Thromb. Vasc. Biol.* 17:889-897 (1997)
	A346	Teng et al., Adenovirus-Mediated Gene Transfer fo Rat Apolipoprotein B mRNA-Editing Protein in Mice Virtually Eliminates Apolipoprotein B100 and Normal Low Density Lipoprotein Production. *J. Biol. Chem.* 1994; 269:29395-29404
	A347	Teng et al. Molecular Cloning of an Apolipoprotein B Messenger RNA Editing Protein, *Science*, 1993; 260:1816-1819

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A348	Teng, Mutational Analysis of Apoliprotein B mRNA Editing Enzyme (APOBEC1): Structure-function Relationships of RNA Editing and Dimerization, *J Lipid Res* 1999; 40(4):623-635
	A349	Thompson et al., The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acid Res.* 1997; 24:4876-4882
	A350	Tom et al., Regulatory Roles of p21 and Apurinic/Apyrimidinic Endonuclease 1 in Base Excision Repair, *J Biol Chem*, 276(52): 48781-48789 (2001)
	A351	Turelli et al., Inhibition of Hepatitis B Virus Replication by APOBEC3G. *Science.* 303(5665):1829(2004)
	A352	Uchegbu et al., Distribution, Metabolism and Tumoricidal Activity of Doxorubicin Administered in Sorbitan Monostearate (Span 60) Niosomes in the Mouse. *Pharm. Res.* 12(7):1019-1024 (1995)
	A353	van Engelen et al., Decreased Immunoglobulin Class Switching in Nijmegen Breakage Syndrome due to the DNA Repair Defect. *Hum. Immunol.* 62: 1324-1327 (2001).
	A354	Van Mater et al., Ethanol Increases apoB mRNA Editing in Rat Primary Hepatocyte and McArdle Cells. *Biochem. Biophys Res. Commun.* 1998; 252:334-339
	A355	Van Parijs et al., Uncoupling IL-2 Signals that Regulate T Cell Proliferation, Survival, and Fas-mediated Activation-induced Cell Death. *Immunity* 1999; 11(3):281-288
	A356	Vaux et al., *Bcl*-2 gene promotes haemopoietic cell survival and cooperates with *c-myc* to immortalize pre-B cells. *Nature* 1988; 335: 440-442
	A357	Veliz et al., Substrate Analogues for an RNA-Editing Adenosine Deaminase: Mechanistic Investigation and Inhibitor Design. *J Am Chem Soc.* 2003 Sep 10; 125(36):10867-76.
	A358	Vocero-Akbani et al. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. *Nat. Med.* 5(1):29-33 (January 1999)
	A359	von Schwedler, vif Is Crucial for Human Immunodeficiency Virus Type 1 Proviral DNA Synthesis in Infected Cells. J *Virol* 1993;67(8):4945-4955
	A360	von Wronski et al., Insulin Increases Expression of Apobec-1, the Catalytic Subunit of the Apolipoprotein B mRNA Editing Complex in Rat Hepatocytes. *Metabolism Clinical & Exp.* 1998; 7:869-873.
	A361	Vora et al., Severe attenuation of the B cell immune response in Msh2-deficient mice. *J. Exp. Med.* 1999;189:471-482
	A362	Wabl et al., Hypermutation at the immunoglobulin heavy chain locus in a pre-B-cell line. *Proc Natl Acad Sci U S A* 1985; 82:479-482
	A363	Wadia et al., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med.* 2004 Mar;10(3):310-5.
	A364	Wedekind and McKay, Purification, Crystallization, and X-ray Diffraction Analysis of Small Ribozymes. *Methods Enzymol* 2000;317:149-168
	A365	Wedekind et al., Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. *Trends Genet.* 2003;19:207-216
	A366	Wiegand et al., A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. *EMBO J.* 23(12):2451-2458 (2004)
	A367	Willerford et al., Developmental regulation of V(D)J recombination and lymphocyte differentiation. Curr Opin Genet Dev 1996; 6:603-609

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A368	Winn et al., Ongoing developments in CCP4 for high-throughput structure determination. *Acta Crystallogr D Biol Crystallogr.* 2002 Nov; 58(Pt 11):1929-1936.
	A369	Winn, An overview of the CCP4 project in protein crystallography: an example of a collaborative project. *J Synchrotron Radiat*, 2003;10(Pt 1):23-25
	A370	Woo et al., Antibiotics Modulate Vaccine-Induced Humoral Immune Response. *Clin Diagn Lab Immunol* 1999; 6:832-837
	A371	Wu et al., Apolipoprotein B mRNA Editing: Validation of a Sensitive Assay and Developmental Biology of RNA Editing in the Rat. *J. Biol. Chem.* 1990; 265:12312-12316
	A372	Wu et al. Normal Perinatal Rise in Serum Cholesterol is Inhibited by Hepatic Delivery of Adenoviral Vector Expressing Apolipoprotein B mRNA Editing Enzyme in Rabbits. *J. Surg. Res.* 85:148-157 (1999)
	A373	Wuerffel et al. Ig Sgamma3 DNA-Specifc Double Strand Breaks are Induced in Mitogen-Activated B Cells and are Implicated in Switch Recombination. *J Immunol* 1997;159: 4139-4144
	A374	Wybranietz et al., Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. *Gene Therapy*. 1654-1664 (2001)
	A375	Xiang et al., Cytidine Deaminase Complexed to 3-Deazacytidine: a "Valence Buffer" in Zinc Enzyme Catalysis. *Biochemistry*. 1996 Feb 6; 35(5):1335-41.
	A376	Xiang et al., The Structure of the Cytidine Deaminase-Product Complex Provides Evidence for Efficient Proton Transfer and Ground-State Destabilization. *Biochemistry*. 1997 Apr 22; 36(16):4768-74.
	A377	Xiang et al., Transition-State Selectivity for a Single Hydroxyl Group during Catalysis by Cytidine Deaminase. *Biochemistry*. 1995 Apr 11;34(14):4516-23.
	A378	Xie et al., "The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1," PNAS 1(21):8114-8119, May 25, 2004
	A379	Xu et al., A Novel 5'-Iodonucleoside Allows Efficient Nonenzymatic Ligation of Single-Stranded and Duplex DNAs. Tetrahedron Lett., 1997, 38:5595-5598.
	A380	Yamanaka et al., Induction of Hepatic Apolipoprotein B mRNA Editing for Reducing Serum Cholesterol Levels: A Breakthrough or A Disaster? *Hepatology*. 24(4):964-966 (1996)
	A381	Yamanaka et al., A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA- editing enzyme, *Genes Dev.*, 1997;11:321-333
	A382	Yamanaka et al., Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. *Proc. Natl. Acad. Sci. USA* 1995;92:8483-8487
	A383	Yamanaka et al., Cloning and Mutagenesis of the Rabbit ApoB mRNA Editing Protein. *J. Biol. Chem.* 1994; 269:21725-21734
	A384	Yamanaka et al., Hyperediting of Multiple Cytidines of Apolipoprotein B mRNA by APOBEC-1 Requires Auxiliary Protein(s) but not a Mooring Sequence Motif. *J. Biol. Chem.* 1996; 271:11506-11510
	A385	Yang and Smith, *In vitro* Reconstitution of Apolipoprotein B RNA Editing Activity from Recombinant APOBEC-1 and McArdle Cell Extracts. *Biochem. Biophys. Res. Commun.* 1996; 218:797-801
	A386	Yang et al., Apolipoprotein B mRNA Editing and the Reduction in Synthesis and Secretion of the Atherogenic Risk Factor, Apolipoprotein B100 Can Be Effectively Targeted through TAT-Mediated Protein Transduction. Molec. Pharm. 61:269-276 (2002)

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary)	Complete if Known	
	Application Number	**10/523,038**
	Intl. Filing Date	**8/5/2003**
	First Named Inventor	**Smith, H., *et al.***
	Group Art Unit	**1648**
	Examiner Name	**Unassigned**

	A387	Yang et al., Induction of Cytidine to Uridine Editing on Cytoplasmic Apolipoprotein B mRNA by Overexpressing APOBEC-1. *J. Biol. Chem.* 2000; 275, 22663-22669
	A388	Yang et al., Intracellular trafficking Determinants in APOBEC-1, the Catalytic Subunit for Cytidine to Uridine Editing of Apolipoprotein B mRNA. Exp. *Cell Res.* 2001;267:153-164
	A389	Yang et al., Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing. *Proc. Natl. Acad. Sci. U.S.A.* 1997; 94:13075-13080
	A390	Yang et al., Partial Characterization of the Auxiliary Factors Involved in Apolipoprotein B mRNA Editing through APOBEC-1 Affinity Chromatography, *J Biol. Chem.*, 1997; 272:27700-27706
	A391	Yang, J., Potent Suppression of Viral Infectivity by the Peptides that Inhibit Multimerizationof Human Immunodeficiency Virus Type 1 (HIV-1) Vif Proteins, Biol Chem. 2002; 278(8):6596-6602
	A392	Yelamos et al., Targeting of non-Ig sequences in place of the V segment by somatic hypermutation. Nature 1995; 376: 225-229
	A393	Yi-Brunozzi et al., Synthetic substrate analogs for the RNA-editing adenosine deaminase ADAR-2. *Nucleic Acids Res.* 1999 Jul 15; 27(14):2912-7.
	A394	Yoshikawa et al. AID Enzyme-Induced Hypermutation in an Actively Transcribed Gene in Fibroblasts. *Science* 2002; 296:2033-2036
	A395	Yu et al., Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome." *Nat Struct Mol Biol.*11(5):435-442 (2004)
	A396	Yu et al., R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. *Nat Immunol* 2003.;4: 442-451
	A397	Yu et al., Essential regions of the tRNA primer required for HIV-1 infectivity. *Nucleic Acids Res.* 28(23):4783-4789 (2000)
	A398	Yu et al., DNA Substrate Length and Surrounding Sequence Affect the Activation-Induced Deaminase Activity at Cytidine. *J Biol Chem.* 2004 Feb 20; 279(8):6496-500.
	A399	Zhang et al., Human Immunodeficiency Virus Type 1 *Vif* Protein is an Integral Component of an mRNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process. *J Virol.* 2000 Sep; 74(18):8252-61.
	A400	Zhang et al., The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003 Jul 3; 424(6944):94-8.
	A401	Zhao et al., Cellular Distribution of Phosphorothioate Oligonucleotide following Intravenous Administration in Mice. *Antisense Nucleic Acid Drug Dev* 1998; 8:451-458
	A402	Zheng et al, Human APOBEC3F Is Another Hhost Factor That Blocks Human Immunodeficiency Virus Type 1 Replication. *J Virol.* 78(11):6073-6076 (2004)
	A403	Zhou et al., Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases. *J Mol Biol* 2002; 321:591-599

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	